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ABSTRACT
O bjective : Previous studies have revealed the 
presence of M1 to M4 muscarinic receptors in 
guinea pig gallbladder, with M3 and M4 receptors 
being claimed to mediate contractions.
M ethods: In the present study, cumulative 
concentration-response curves to carbachol 
were constructed in the absence and presence of 
darifenacin, which has greater selectivity for M3 
over M4 receptors, in guinea-pig gallbladder.
R e su lts : Darifenacin caused concentration- 
dependent dextral shifts of the carbachol curve, 
however, at 1 pM, it also caused a degree of 
insurmountable antagonism. Using a novel 
analytical approach, we obtained a pKB estimate 
for darifenacin (7.51 ± 0.14) that is in excellent 
agreement with its affinity for M2/M4, but not M3 
receptors.
C o n clus io n : Given our previous demonstration 
that M2 receptors are unlikely to contribute to 
muscarinic contractions in this tissue, our current
findings provide pharmacological evidence for a 
predominant role of M4 muscarinic receptors in 
guinea pig gallbladder contractions.
K e y  W o rd s : Muscarinic receptor, Guinea-pig, 
Gallbladder, Contraction, Darifenacin.
IN T R O D U C T IO N
M uscarinic acetylcholine receptors play an 
important role in regulating smooth m uscle 
contractility (1). Although abundant evidence 
exists to suggest that the muscarinic M3 receptor 
is the predominant subtype causing a contraction 
in most smooth muscle preparations (2), there 
are exceptions to this general observation. One 
notable example is the guinea pig gallbladder, 
where m uscarinic receptor-mediated smooth 
muscle contraction helps to control bile outflow in 
response to feeding; despite previous claim s of 
functional M3 receptors being present in this 
tissue (3-6), a combination of biochemical and 
organ bath experim ents have revealed the
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presence of M ,, M2> M3 and M4 muscarinic 
receptor subtypes (7-11).
A major difficulty in ascribing functional roles to 
subtypes of muscarinic receptors has long been 
the lack of se lective  antagonists that can 
differentiate between receptors mediating the 
same response (1). Nevertheless, a comparison 
of the potencies of a group of antagonists may 
still be used to determ ine the possible 
contribution of different subtypes to a particular 
response. Using this strategy, we provided 
evidence for a functional role of both M3 and M4 
receptors in mediating guinea-pig gall bladder 
contractions (11). However, that study was 
unable to determine which of the two subtypes 
played the predominant functional role. In the 
present study, we have utilized the antagonist, 
darifenacin, which is at least greater than 50 
times more selective for the M3 (pKB approx. 9) 
over the M4 receptor (pKB approx. 7.5) (12,13), 
and investigated its effects on carbachol- 
mediated contractions in guinea-pig gallbladder.
M A T E R IA L  A N D  M E T H O D S
Guinea-pigs of either sex (300-350 g) were killed 
by C 0 2 asphyxiation. Gallbladders were then 
removed and longitudinal strips were prepared 
and mounted in an organ bath containing Krebs 
solution (composition in mmol/l; NaCI, 118.4; 
KC I, 4 .7 ; C aC I2, 2 .5 ; M g S04, 1.2; N aH C 03, 25.0; 
KH2P 0 4, 1.2; glucose, 11.1) at 37°C bubbled 
with a mixture of 95 %  0 2 and 5 %  C 0 2. T issues 
were allowed to equilibrate for 2 h under a resting 
tension of 0.5 g., and isometric contractions were 
recorded on a polygraph (G rass Model 7) via a 
force-displacement transducer (G rass FT03).
Control cum ulative concentration-response 
curves were constructed to carbachol (Sigma, St. 
Louis, USA). An interval of 45 min was then 
allowed during which the tissues were washed 
with Krebs solution. A second concentration- 
response curve to carbachol w as then 
constructed in the absence or presence of 
darifenacin. One or two concentrations of the 
antagonist were used for each strip.
Normalized concentration-response data were 
fitted to a three-parameter Hill equation using a 
pre-release version of Prism 4.0 (GraphPad
Software, San Diego, CA). Because the highest 
concentration of darifenacin (1 pM) caused a 
significant reduction in the maximal response to 
carbachpl (see R esu lts), we determined 
equieffective agonist concentrations, in the 
absence or presence of antagonist, at a 
response level close to the tissue minimum 
(15%) in order to derive antagonist potency 
estimates. The validity of this analytical approach 
has been demonstrated previously (14-16). The 
agonist p E C 15o/o va lues were fitted to the 
following equation:
pEC is%  = -log ([B]s + 1 0 -PK) -  logo (1)
where [B] denotes antagonist concentration, pK 
and logc are fitting constants, and s is equivalent 
to the Schild slope factor; when s=1, pK=pKB 
(15). For presentation purposes, the relationship 
between the estimated pKB and the shift of the 
agonist concentration-response curves was 
displayed as a Clark plot (17).
Data are shown as mean ± s.e .m . Estimates of 
agonist concentration-response curve maxima 
were compared by one-way ANOVA. P < 0.05 
was taken as significant.
RESULTS
Carbachol caused concentration-dependent 
contractions in guinea-pig gallbladder 
longitudinal muscle strips, with a pEC50 value of 
5.63 0.18 (n = 7). The addition of darifenacin 
caused dextral shifts of the carbachol curve (Fig. 
1A). However, the highest concentration of 
darifenacin also caused a significant reduction in 
the maximal response to carbachol, an 
observation not consistent with the expectations 
of simple competitive antagonism.
Because the insurmountable effect of 1 pM 
darifenacin meant that the carbachol p E C 50 
values do not all represent equieffective agonist 
concentrations, we fitted the data to equation (1) 
utilizing equieffective agonist concentrations that 
were determined at the p E C 15°/o response level 
(Fig. 1 A). The analysis using this method yielded 
a pKB value of 7.51 0.14 (n = 25). In this
analysis, the Schild slope parameter was not 
significantly different from unity and was 
constrained as such for the estimation of the 
antagonist pKB value.
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F ig - 1 :  (A) Concentration-response curves of carbachol in the 
absence (□ ) or presence of darifenacin 0.01 (■), 0.1 (O) 
or 1 pM (A )  in guinea-pig gallbladder. Also indicated on 
the Figure is the 15% response level (dashed line) that 
was used for the derivation of equieffective agonist 
concentrations for subsequent determ ination of the 
antagonist pKB from Equation (1) of the Materials and 
Methods. Data points represent the means of 4-8 
experiments. '  S ignificantly different (P < 0.05) than the 
control maximal response to carbachol. (B) Clark plots of 
the interaction between increasing concentrations of 
darifenacin with carbachol. The antagonist pKB estimate 
was firs t derived by nonlinear regression analysis 
according to equation (1) in the Materials and Methods, 
and was subsequently used in the construction of the 
Clark plot.
D ISCUSSIO N
Studies on most smooth muscle preparations 
have demonstrated a major role for functional 
m uscarinic M3 receptors in mediating
contractions, even though these tissues
invariably contain a mixture of m uscarinic 
receptor subtypes (2). In a few smooth muscle 
preparations, however, contractile responses
may be mediated by m uscarin ic receptor 
subtypes other than the M3 receptor (18-22).
In the guinea-pig gallbladder, Von Schrenck et al.
(6) reported that carbachol-induced inhibition in 
adenylate cyc lase , but not stimulation of 
phosphoinositides, was pertussis toxin sensitive, 
indicating the presence of more than one subtype 
of m uscarinic receptors. Subsequently, 
biochemical and functional studies have revealed 
the presence of M,, M2, M3 and M4 muscarinic 
receptor subtypes in this tissue (23 ,24 ,8 ,9 ). Of 
these subtypes, a predominant functional role in 
guinea pig gallbladder smooth m uscle was 
suggested for the M3 receptors (3-6), but we 
recently provided evidence for the coexistence of 
both functional muscarinic M3 and M4 receptor 
subtypes mediating C a 2+ mobilization in this 
tissue (11).
The present study extended our previous work by 
utilizing darifenacin to differentiate the 
m uscarinic receptor subtype involved in 
carbachol-mediated contractions of the guinea 
pig gallbladder. Darifenacin is classed as an M3- 
selective m uscarinic receptor antagonist, 
showing 100-fold selectivity for M3 receptors over 
M2 receptors in atria and 30 fold over M, 
receptors in rabbit vas deferens (12). The pK, 
va lues against human cloned m uscarin ic 
receptors have been reported as: M ,, 8 .15; M2, 
7.35; M3, 9.12; M4, 7.34; M5, 8.03 (13).
Although darifenacin w as able to inhibit 
carbachol-mediated contractions in our 
preparation, the highest concentration used here 
resulted in a significant degree of insurmountable 
antagonism (Fig . 1A). Th is property of 
darifenacin has been reported previously at pig, 
rat and dog bladder smooth muscle, but not in 
rabbit and mouse bladder (25-29). Although the 
reason for the apparent insurmountability of 
darifenacin antagonism is not known, it is 
possibly related to slow binding kinetics at the 
muscarinic receptors, relative to the time scale of 
the measured responses, as previously noted 
with other muscarinic receptor antagonists (14). 
Irrespective of m echanism , apparent 
insurmountable antagonism  invalidates the 
classic approaches for quantifying competitive 
antagonism that rely on the comparison of 
agonist E C 50 values, because these values no 
longer represent equieffective agonist
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concentrations and hence the analysis is no 
longer response-null. As a consequence, the 
use of E C 50 values in the determination of 
antagonist potency under such conditions leads 
to an underestimation of the true antagonist 
potency (14-16). However, we have previously 
demonstrated in different cell and tissue 
preparations how the impact of this 
underestimation can be minimized by choosing 
truly equieffective agonist concentrations at an 
appropriate response level (14-16). In the 
present study, we utilized the 15% response level 
in equation (1).
Using our analytical method, we derived a pKB 
estimate for darifenacin of 7.51 that is more than 
an order of magnitude lower than any previous 
estimates of the affinity of darifenacin for the M3 
receptor, but in excellent agreement with its 
affinity for either the M2 receptor or the M4 
receptor (13). Because we have previously used 
a series of selective antagonists to rule out a 
functional role for muscarinic M2 receptors in 
guinea pig gallbladder (11), our current findings 
with darifenacin lead us to conclude that the 
major functional muscarinic receptor subtype in 
this preparation is the M4 receptor.
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